Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
University of Chicago
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University College, London
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
University of New Mexico
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
BTG International Inc.
University Hospital Schleswig-Holstein
Therapeutic Advances in Childhood Leukemia Consortium
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Prince of Wales Hospital, Shatin, Hong Kong
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Dutch Childhood Oncology Group
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences